Despite successes in animals, cytokine gene expression selectively in human tumors is difficult to achieve owing to lack of efficient delivery methods. Since interleukin (IL)-2-activated natural killer (A-NK) and phytohemagglutinin and IL-2 activated killer T (T-LAK) cells, as previously demonstrated, localize and accumulate in murine lung tumor metastases following adoptive transfer, we transduced them to test their ability to deliver products of genes selectively to tumors. Assessments of transduction efficiency in vitro demonstrated that adenoviral transduction consistently resulted in high (460%) transduction rates and substantial expression of transgenes such as GFP, Red2, luciferase, b-galactosidase and mIL-12 for at least 4 days. In vivo experiments illustrated that Ad-GFP transduced A-NK and Ad-Red2 (RFP) transduced T-LAK or mIL-12 transduced A-NK cells localized 10-50-fold more or survived significantly better than mock transduced cells, respectively, within lung metastases than in the surrounding normal lung tissue. Most importantly, mIL-12 transduced A-NK cells provided a significantly greater antitumor response than non-transduced A-NK cells. Thus, adoptive transfer of A-NK and T-LAK cells represents an efficient method for targeting products of genes to tumor sites.
Introduction
Therapy of cancer involving cytokine genes is a new approach that has already shown promising results, especially in animal models. For example, ex vivo incorporation of a retroviral vector expressing interleukin (IL)-15 into colon carcinoma cells 1 or IL-18 cDNA into B16 cells 2 inhibited tumor growth in vivo following inoculation, and resulted in development of protective, systemic immunity against the tumors. In addition, IL-12 transduced tumor cells were not only capable of generating local but also systemic antitumor responses when intratumorally injected along with IL-15 protein. 3 IL-2 transduced colon carcinoma cells induced both specific and nonspecific antitumor immune responses depending on the amount of IL-2 produced. 4 While these studies clearly demonstrate the very potent antitumor effects of intratumoral cytokine expression, difficulties targeting the cytokine gene expression selectively to tumors remain a major limitation of this therapeutic modality. In those few, select cases where the tumor is accessible, direct injection gene-therapy strategies have been widely explored and demonstrated a high degree of success. For example, when intratumorally injected as viral vectors containing the genes for IL-2, IL-18 or interferon g (IFNg) retarded the growth of subcutaneous tumors and prolonged survival. [5] [6] [7] As an alternative to injection of viral vectors directly into tumors, several groups have injected non-transformed cells, such as fibroblasts, transduced with cytokine genes into established tumors. Bubenik et al. 8 injected IL-2 gene transfected fibroblasts peritumorally into nude mice and found a growth inhibition of human carcinoma cell tumor xenografts. Likewise, Duda et al. 9 demonstrated an inhibition of colon carcinoma growth when tumor cells were coinjected s.c. with IL-12 transduced 3T3 fibroblasts. Cytokine gene delivery directly to tumors has also been achieved by employing cationic liposomes. Ryuke et al. demonstrated a greater reduction in subcutaneous melanoma lesions when IFNb plasmids, complexed to liposomes, were intratumorally injected as compared to recombinant IFNb alone. The antitumor effect appeared to be dependent on the presence of NK cells. 10 Although fibroblasts are easily transduced with a number of viral vectors, using transduced antitumor immune cells instead of fibroblasts provides an effector cell capable of responding directly to the cytokines they themselves deliver. In this scenario, antitumor responses may be generated by the expressed cytokines via both the delivery vehicle and the endogenous immune cells, enhancing the overall response. For example, Nishioka et al. 11 have shown reduction in tumor burden following intratumoral injection of dendritic cells retrovirally transduced to express IL-12. DCs, adenovirally transfected to express IL-12, have also been shown to reduce colon adenocarcinoma metastases in the liver and elicit systemic antitumor responses when injected intraportally. 12 In the majority of cases, though, tumors are disseminated and cannot all be reached by direct injection. Thus, in order to selectively target the tumor, antibody-cytokine fusion proteins 13 and modified adenoviruses 14 have been tested. Antibody-IL-12 together with antibody-TNFa fusion proteins were effective at eliminating small subcutaneous tumors but did not completely protect against rechallenge. 13 Bauerschmitz et al. 14 showed that modified adenovirus was more efficient than native virus at impeding growth of tumors. Additionally, Sakurai et al. 15 showed systemic, i.v. delivery of IFNb or IFNg lipoplexes to be effective prophylactically as well as therapeutically against colon carcinoma lung metastases. However, it was found that empty lipoplexes performed nearly as well as IFNg lipoplexes on many counts. Thus, despite the numerous methods developed for delivering cytokines or cytokine genes to tumors they still remain relatively ineffective in their selectivity.
We have shown that lymphokine activated killer (LAK) cells, namely IL-2 activated natural killer (A-NK) and IL-2 and phytohemagglutinin (PHA)-activated T (T-LAK) cells, localize and accumulate within lung tumor metastases when administered intravenously. 16, 17 Based on their impressive ability to accumulate selectively at tumor sites (regardless of the antigen expression by the tumor), we hypothesize that A-NK or T-LAK cells transduced with cytokine genes may be used as vehicles to target cytokines to sites of tumors. This would, depending on the cytokine genes employed, result in a local production of innate and adaptive immune regulators, thereby limiting concerns as to their systemic availability, at the least, or toxicity, at the most.
Here we show that A-NK and T-LAK cells can be successfully transduced ex vivo with adenoviral vectors to express a variety of products of genes such as eGFP, RFP, luciferase, and, as an example of a pro-inflammatory cytokine, murine IL-12. Furthermore, adoptively transferred, adenovirally transduced A-NK cells were found in five-fold or higher density within B16 melanoma and 3LL tumors than in normal lung tissue after transfer into tumor-bearing mice. The A-NK cells expressed the gene product (eGFP) in the tumors for up to 72-96 h postinjection. T-LAK cells, as well, were capable of expressing various genes selectively within tumor metastases. Most importantly, regarding cytokine delivery, mIL-12 transduced A-NK cells demonstrated greater survival and antitumor effectiveness compared to mock transduced cells, at low doses of exogenous IL-2. On this background, we suggest that adenovirally transduced A-NK and T-LAK cells can be used for the selective delivery to tumors of an array of cytokines as well as other transgenic products displaying antineoplastic effects.
Materials and methods
Animals, tumor cell lines and viral vectors C57BL/6 and B6. P1-Thy-1aCy mice were purchased from Jackson laboratories (Bar Harbor, ME). The animals were housed in a specific pathogen free facility and their use was authorized by the University's IACUC committee. F10 B16 melanoma cells and the Lewis lung, 3LL (ATCC), carcinoma cells, both syngeneic to C57BL/ 6 mice, were maintained in complete media (CM), which is RPMI1640 medium (Life Technologies, Gaithersburg, MD) supplemented with 10% heat inactivated fetal calf serum, 2 mM glutamine, 0.8 g/l streptomycin and 1.6 Â 10 5 U/l penicillin. Adherent tumor cells were harvested with 0.02% ethylenediaminetetraacetic acid (EDTA) and washed in RPMI medium. The recombinant adenoviral vectors used in this study were E1/E3 deleted replication-defective type 5 adenoviruses 18 (obtained from the Preclinical Vector Core Facility, University of Pittsburgh). The cDNA encoding Lac Z, murine IL-12, eGFP or luciferase was inserted into the E1 region with gene expression driven by the early promoter of the human cytomegalovirus. High titer recombinant adenoviruses were generated as described previously, 19 by CreLox driven homologous recombination and permissive replication in CRE8 cells, a 293 cell line (ATCC, MD) that expresses Cre recombinase. Viral titers were determined by optical density at 260 nm (OD 260 ) where 1 OD unit ¼ 10 12 viral particles. 20 Polylysine (pK7) and RGDfiber-modified adenoviral Lac Z vectors were gifts from Dr Imre Kovesdi (GenVec, Rockville, MD).
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A-NK cell preparations A-NK cells were generated from congenic B6.P1-Thy1aCy spleens as previously described. 22 Briefly, spleens were asceptically obtained and a single-cell suspension was generated. Red blood cells were lysed by incubating the splenocytes with red blood cell lysing buffer (SigmaAldrich, St Louis, MO) at 1 ml/spleen for 2 min with swirling every 30 s. Following filtration through a 70 mm filter, the remaining bulk splenocytes were plated in culture flasks, maintained at 371C and 5% CO 2 in CM and 6000 IU/ml human recombinant IL-2 (kindly provided by the Chiron Corporation, Emeryville, CA). Up to 72 h after the start of culture, non-adherent cells were passaged to new flasks while the adherent cells were given fresh CM and IL-2 as needed, as described previously. 23 These plastic-adherent, A-NK cells were used on days 5 or 6 of culture. Routinely, these A-NK cells were
T-LAK cell preparations Splenocytes were obtained as described above and transferred to T150 plastic flasks at 2 Â 10 5 cells/ml of complete medium. The cells were activated with 600 IU/ ml of rhIL-2 and 0.4 mg/ml of PHA-P (phytohemagglutinin-P; DIFCO, Detroit, MI). After 2 days of incubation, clusters of T cells were transferred to 50 ml tubes and sediments were allowed to form for 5-7 min before the Tumor targeting products of genes S Goding et al supernatant was gently removed. The cell sediment was resuspended at 1 Â 10 5 cells/ml of fresh CM containing 600 IU IL-2/ml. Three days later, the cells were harvested, washed twice and resuspended in RPMI-1640. Routinely, the T-LAK cells were found to be 495% Thy1, 495% asGM1 þ , 490% CD8 (Lyt-2) þ , 490% CD3 þ , but o5% NK1.1 þ and o2% CD4 (L3T4) þ , in agreement with previous findings. 17 
Viral transductions
A-NK or T-LAK cells were collected (A-NK cells with 0.02% EDTA), washed with CM and resuspended in RPMI without serum at a concentration of 10 Â 10 6 cells/ ml (or 40 Â 10 6 cells/ml for in vivo studies). Virus was added at various multiplicities of infection (MOIs) and the cell suspensions were incubated at 371C for 90-120 min. During the incubation period the tubes were gently shaken every 15 min. The cell suspensions were then placed into culture flasks containing CM and 6000 or 600 IU/ml IL-2 for A-NK or T-LAK, respectively. Cells were again incubated at 371C for the indicated number of hours for each assay. Before each assay and the in vivo tumor experiments, cells were harvested and washed three times in a large volume or in excess CM to remove unincorporated virus.
Flow cytometry
Adenovirally transduced A-NK cells were harvested, washed and fixed in 0.25% paraformaldehyde. Samples were run on a Beckman Coulter Epic XL-MCL FACs machine, collecting 5000 events. Data obtained from histograms was compared to non-transduced control groups.
Luciferase, b-galactosidase and cytokine production The production of luciferase and b-galactosidase were assessed using substrates from Luciferase Assay System (Promega, Madison, WI) and Galacto-Light Plus (Tropix, Bedford, MA), respectively, according to the manufacturer's protocol. Samples were analyzed on an Autolumat LB-953 luminometer (Berthold Technologies, Bad Wildbad, Germany). Cytokine production was measured using sandwich ELISAs on supernatants for murine IL-12p70 and IFNg (Endogen, Woburn, MA). Injections of PEG-IL-2, at 60 000 IU/ml, were given two times within 24 h of the injection of the A-NK cells.
Adoptive transfer experiments

Estimation of adoptively-transferred A-NK and T-LAK cell infiltration of lung metastases and survival analysis
Using the Thy1.1/1.2 congenic system the infiltration of the transferred A-NK cells was determined as described previously. 22 Briefly, one half of organ samples obtained from mice at various time points were fresh frozen at À701C. Eight-micron-thick sections of the organs were stained with PE-conjugated, anti-Thy1.1 Ab (Pharmingen) at a 1:200 dilution and compared to PE-conjugated IgG2b Ab controls. The other half of the organ samples were fixed in 1% paraformaldehyde for 3 h then 30% sucrose overnight. These fixed tissues were then snap frozen, sectioned, and GFP þ A-NK, or RFP þ T-LAK, cells were identified by fluorescence microscopy. Fluorescent and DIC images of the tissue sections were obtained using a Nikon fluorescent microscope and analyzed for cell numbers using MetaMorph image analysis software. 22 Mice were code numbered and monitored for survivability by two observers with no knowledge of the code. When reaching a premorbid condition, as defined by our IACUC, mice were killed and the lungs were removed, dried and weighed (the average dry weight of the lungs from the mock transduced A-NK and AdIL-12 transduced A-NK groups ( Figure 6 ) were 0.18970.01 versus 0.16370.03 g, respectively, ensuring that the mice, at the time of killing, had reached the same stage of tumor development).
Statistical analysis
Two-tailed, unpaired Student's t-tests were performed with a 95% confidence interval. For survivability curves, data were plotted according to the Kaplan-Meier method with statistical significance determined using the log-rank test. A concern of viral transduction, especially at high MOIs, is that of toxicity to the transduced cells. The viability and proliferative capacity of A-NK and T-LAK cells transduced at increasing MOIs was therefore examined. Trypan blue dye exclusion tests revealed a high viability of both A-NK cells and T-LAK cells at 24 h at all MOIs tested, indicating a low immediate toxicity of the virus (data not shown). However, while analysis of cell growth 1-5 days after transduction demonstrated that all cells continued to grow, it was clear that the growth rate of cells transduced at higher MOIs was somewhat suppressed -especially during the first days after transduction -compared to non-transduced control cells and cells transduced at lower MOIs (Figure 1c ).
Functional enzymes, luciferase and b-galactosidase are expressed by transduced A-NK cells It was of critical importance to demonstrate that gene delivery and expression in A-NK cells could result in production of proteins other than GFP. Adenoviral vectors with the genes for luciferase (Ad-luc) and b-galactosidase (Ad-b-gal), respectively, were therefore employed. After 48 h of culture, lysates of Ad-luc transduced A-NK cells showed a marked increase, more than 100-fold increase in light activity seen after the addition of D-luciferin substrate as compared to nontransduced cells (Figure 2a) . Likewise, cells transduced with Ad-b-gal reacted strongly when assayed with Galacto-Light Plus, a luminescent substrate system (Figure 2b) . Modified adenoviral vectors, such as Ad-RGD and -PK7 (Figure 2b ) enhance uptake through unconventional receptors, the integrin and heparan sulfate receptors, respectively. Using these vectors, we achieved a greater transduction efficiency and gene expression of the A-NK cells compared to the unmodified Ad5 vector. Taken together, these data demonstrate that in addition to susceptibility to GFP gene transduction, A-NK cells can be efficiently transduced to express genes coding for various enzymes.
Transduced A-NK and T-LAK cells can produce a potent regulator of adaptive immunity The next important step was to investigate whether A-NK and T-LAK cells could be transduced to overexpress cytokines involved in antitumor immune responses. To test the production of such an agent, an adenoviral vector expressing murine IL-12, a cytokine known for its ability to stimulate NK and T cells 24, 25 and to enhance CTL response and promote Th1 immunity, 26, 27 was employed. As seen in Figure 3a , A-NK and T-LAK cells were successfully transduced with the Ad-mIL-12 vector to secrete high amounts of mIL-12. The production of mIL-12 by transduced A-NK cells followed similar kinetics as the GFP production, namely with a peak expression around the 48-h time point (compare Figure 1b with Figure 3b ). The functionality of the mIL-12 was confirmed by demonstration of an elevated IFNg production from the transduced A-NK and T-LAK cells compared to non-transduced cells (Figure 3c ). The IFNg production by T-LAK cells transduced with the 
Selective tumor homing by adoptively transferred, A-NK and T-LAK cells transduced with various genes
Having demonstrated the success of A-NK and T-LAK cell adenoviral transduction, we next studied the ability of the transduced cells to localize at tumor sites upon adoptive transfer and to express the transgene while in the tumor tissue. Mice were injected with 3LL or B16 tumor cells to induce pulmonary metastases and 10 days later, eight million Ad-eGFP transduced A-NK cells were injected i.v. Exogenous PEG-IL-2 injections were given every 12 h to support the transferred cells as previously described. 28 At various times organs were harvested, fixed, cryosectioned and analyzed for the presence of A-NK cells and GFP. As early as 24 h after injection, the density of the transferred A-NK cells was, as expected, significantly higher in the tumor tissue compared to the normal lung tissue, and the A-NK cell density in the tumor tissue continued to increase for the next 3 days A-NK or T-LAK cells were transduced with the indicated MOI of Ad-mIL12. Cells were washed after 24 h culture and given fresh media. 24 h later, supernatants were collected and analyzed for the presence IL-12 (a) or IFNg (c). 25 MOI for T-LAK not tested (*). (b) 2 Â 10 6 ANK cells were transduced with the indicated MOI of Ad-mIL-12. Supernatants were harvested at various times and assayed using ELISA. Values are given in pg/ml for the total amount of mIL-12 present in the culture flask by multiplying the number of ml of supernatant by the ELISA readings for a 1/10 dilution of samples.
Tumor targeting products of genes S Goding et al the tumor tissue than in the surrounding normal tissue from 24 and until 96 h. Figure 4 shows the presence of GFP expressing A-NK cells at 72 h in lung 3LL (Figure 4a ) and in B16 (Figure 4b) tumors. As could be expected, though, based on the loss of GFP expression from the cells from 72 h after transduction (Figure 1) , expression was maximal at 48 h and declined thereafter (Figure 4c ) but remained significantly greater within the tumor tissue compared to normal tissue at all times evaluated, P-value o0.05. As seen in Figure 4d , T-LAK cells transduced to express RFP were found at a ratio of 10:1 in tumor tissue compared to normal lung tissue 48 h after injection. Thus, although less transducable than A-NK cells, T-LAK cells may also serve to localize products of genes to tumor tissues.
We also analyzed liver and spleen tissue sections for the presence of transduced cells, to rule out the possibility of nonspecific targeting. We found GFP expression in the liver, for example, to be only 1.95% of that of lung tumors, with a similarly low density of Thy1.1 positive cells. The density of NK cells, as well as GFP expression, in other organs (such as kidneys and spleen) appeared to be substantially lower than the GFP expression in liver.
To illustrate the benefit of expressing a cytokine selectively within lung tumors, A-NK cells were transduced with Ad-mIL-12. B16 tumor bearing mice received five million Ad-mIL-12 or mock transduced ANK cells along with two injections of full dose of IL-2 (60 000 IU/ ml) only. Cells were quantitated in lung tumor metastases 72 h after adoptive transfer. At this time we discovered a substantially greater number of exogenous A-NK cells within lung tumors when they were first ex vivo transduced to express mIL-12 ( Figure 5a ) than if they had been mock transduced (Figure 5b) . We also found a Tumor targeting products of genes S Goding et al significant antitumor response, as determined by mouse survivability, which accompanied the enhanced cellular survival of mIL-12 transduced cells. We found that mock transduced A-NK cells provided no benefit in mean survival of mice compared to that seen with the exogenous IL-2 only treatment group ( Figure 6 ). In contrast, mice receiving mIL-12 transduced A-NK cells survived significantly longer than IL-2 treated mice and mice treated with mock transduced cells ( Figure 6 ; 26 days compared to 16 days for mock transduced mice; P-value o0.005). We, therefore, conclude that A-NK cells can be used to deliver transgenic products, including pro-inflammatory cytokines such as IL-12, to sites of tumors to augment antitumor responses.
Discussion
Activation of macrophages involved in innate immunity, of dendritic cells in initiating adaptive immunity, and of T cells providing effector function and memory all depend on cytokine interactions. Numerous studies describe how administration of cytokines 29, 30 can help boost these immune reactions. For instance, Kodama et al. 29 and Hashimoto et al. 30 have demonstrated that the administration of recombinant IL-12 or IL-18 resulted in a noticeable antitumor effect in mice. Furthermore, the effects of IL-18 together with IL-2 were greater than either cytokine alone in reducing the number of lung metastases in mice. 31 However, caution must be taken in administering combinations of recombinant cytokines for therapeutic purposes, such as IL-2 and IL-12 32 or IL-12 and IL-18, 33 or even IL-18 alone, 34 in that fatal toxicity may result. There is a fine balance, therefore, in ensuring that the amount of cytokine administered is sufficient to activate and sustain the immune system, but not so elevated that treatment-limiting toxicity is induced. In order to reduce toxicity, it seems logical to directly target the cytokine(s) to sites of established tumors. While the application of fibroblasts transduced with cytokine genes has delivered proof that selective presence of cytokine in tumors leads to tumor reduction with very little or no toxicity, this approach is limited by the fact that the cells must be injected directly into the tumors. Viral vectors or liposome complexes, when injected intravenously, may be mistargeted, degraded, or may never locate and infiltrate the actual tumor. 35 Furthermore, along with injection of recombinant cytokines, their systemic application may lead to development of toxicity. These, and other, shortcomings prompted us to investigate the use of lymphocytes capable of localizing at tumor sites as delivery vehicles of products of genes, including cytokines. We focused on A-NK and T-LAK cells as vehicles Time (in days) Figure 6 Selective mIL-12 expression in lung metastases provides for an overall greater survival in mice. Survival of mice (from Figure 5 ) was determined in a blinded fashion as described in Material and Methods and plotted using the Kaplan-Meier method. Log-rank test demonstrated a significant difference in survival time between mice receiving IL-2 only or mock transduced A-NK cells and mIL-12 transduced A-NK cells (P-value o0.005, n ¼ 5).
for tumor-selective targeting of transgenes, since we have previously demonstrated their ability to localize to remote, disseminated lung tumor metastases.
It was important to demonstrate, first of all, that the A-NK and T-LAK cells could in fact be successfully transduced with genes. Second, we wanted to determine if A-NK and T-LAK cells could express immunologically relevant genes, in particular those pertaining to cytokines. Finally, we needed to illustrate that the transduced cells maintain the capacity to traffic to tumors, without a loss in viability or ability to express the transgene.
For the gene transduction, we focused on adenoviral vectors since they were capable of infecting A-NK and T-LAK cells at high rates, could be generated to high titers, and could introduce genes of up to 8 kb into cells. 36 In fact, transduction of A-NK and T-LAK cells with other types of vectors, for example, retrovirus and lentivirus, resulted in very low transduction rates (0.1-10%). Since A-NK and T-LAK cells divide for only a limited amount of time (2-4 weeks), cloning of a relatively low number of successfully retro-and lenti-virally transduced A-NK/T-LAK cells, therefore, was not feasible. We show here that a variety of genes, such as GFP, RFP, luciferase, as well as murine IL-12, could be successfully expressed by a high percentage of the A-NK and T-LAK cells. Judged by both GFP and mIL-12 expressions, the transduction efficiency was high and expression persisted, although reduced considerably with time, to at least a week after transduction. Thus, A-NK cells that were greater than 80% GFP-positive at 48 h after Ad-GFP transduction, fell below 30% GFP-positive cells by day 7. This may be explained by the fact that adenoviruses are unable to integrate their genetic material into the host genome, and therefore incapable of replicating. Thus, the originally delivered viral genes became diluted with successive rounds of division of the rapidly proliferating A-NK and T-LAK cells. In addition, inactivation of the CMV promoter of the adenoviral vectors also contributes to the declining gene expression. 37 Somewhat surprisingly, T-LAK cells proved harder to transduce than A-NK cells. While up to 80% of the A-NK cells expressed eGFP at 24-48 h after transduction, only about 30% of the T-LAK cells, transduced under the same conditions, were eGFP þ at this time. Whether this results from a lower expression of coxsackie and adenovirus receptor (CAR) on the T-LAK cells compared to A-NK cells is under investigation. To improve the transduction rate of T-LAK cells, it may be possible to employ fiber knob-modified or biotinylated adenoviral vectors 38 that can be taken up through various receptor interactions. A preliminary experiment in our laboratory indicates that DMRIE-C, a liposome-cholesterol reagent used to enhance DNA/RNA and virus transfection, 39, 40 improved the T-LAK cell transduction rate. It is also possible that other modified adenoviral vectors such as Ad-RGD and -PK7, which improved transduction of A-NK cells, will also be able to improve the transduction efficacy of T-LAK cells.
We also tested the ability of adenovirally transduced A-NK and T-LAK cells to express functional, antitumor cytokines. Both cell types were transduced with an AdmIL-12 vector. As early as 24 h after transduction, both cell types produced significant amounts of mIL-12, with A-NK cells producing greater amounts. Again, the expression of this gene was evident for more than 72 h. Also, the mIL-12, as well as mIL-18 (data not shown), gene transduction led to the induction of secondary cytokine/chemokine production. Levels of IFNg, for example, were markedly elevated in supernatants from A-NK and T-LAK cells transduced with mIL-12 (and mIL-18, data not shown) genes as compared to non or mock transduced cells. In spite of the low mIL-12 levels generated by transduced T-LAK cells, the levels of IFNg generated by the mIL-12 transduced T-LAK cells were equal to those generated by mIL-12 transduced A-NK cells, as confirmed from separate experiments. This is encouraging considering the significantly greater amount of mIL-12 produced by A-NK cells compared to T-LAK cells. Apparently, the mIL-12 produced by the T-LAK cells is fully capable of boosting downstream immune responsiveness as evidenced by the robust production of IFNg.
Having demonstrated the efficiency of adenoviral vectors to transduce A-NK and T-LAK cells, we tested whether this procedure would translate to selective targeting of gene expression in our lung tumor model. Although previous reports have indicated A-NK and T-LAK cells possess the ability to home to and infiltrate lung metastases, we were uncertain of any deleterious effects adenoviral transduction may have on this. However, we did not find any indication of negative effects of gene transduction on tumor localization since Ad-eGFP and Ad-Red2 transduced A-NK and T-LAK cells, respectively, localized to tumors to the same degree as non-transduced cells. 22, 41 Thus, for both A-NK cells and T-LAK cells, increasing cell densities within the metastases were found up to 96 h. Accordingly, the density of GFP-positive cells also increased after injection, but, in contrast to the cell density, as measured by immunostaining, measurable GFP declined after 48 h. We believe this is caused by both inactivation of the CMV promoter and dilution (due to cell proliferation) of the transgene, as discussed above. From these data, it is clear that adenoviral transduction of A-NK and T-LAK cells does not hinder their ability to traffic to and infiltrate lung tumors. In addition, the transduction process does not appear to be toxic to the cells, but results in successful expression of the transgenes by the tumor infiltrating A-NK and T-LAK cells.
The gradual loss of GFP or RFP signal due to dilution of the genetic material for each A-NK and T-LAK cell division clearly reduces the usefulness of these fluorescence products as markers for individual cells. However, as long as all A-NK and T-LAK progeny remain at the tumor site, one would expect that the overall gene expression would only become reduced due to inactivation of the viral genes. Thus, sufficient levels of proimmune cytokine may be achieved by the combined effort of many cells each producing a modest amount of cytokine. Moreover, the A-NK/T-LAK cells infiltrating the lung tumors are confined to an environment with very little extracellular fluid. Therefore, even the production of a numerically modest number of cytokine molecules may result in cytokine concentrations sufficient to stimulate both the exogenously delivered and endogenous immune effector cells. This cytokine benefit has been clearly demonstrated from our results illustrating a substantially improved effector cell survival and antitumor effect by mIL-12 gene transduced effector cells compared to mock transduced cells. It should be noted that the antitumor effect of the transduced cells was maintained even in the presence of only two initial injections of exogenous IL-2 support, a key factor in eliminating systemic toxicity, which usually appears after two to three days of exogenous IL-2 treatment. Although the treatment of mice receiving mIL-12 transduced cells did not result in complete cure, these mice survived significantly longer compared to mock transduced cell recipient mice. With repeated adoptive transfer or multiple/different cytokines (as in ongoing experiments), it is imaginable that greater survival could be attained, ultimately leading to curative benefits.
All taken together, our data demonstrate the potential of A-NK and T-LAK cells to deliver antitumor products of genes, including cytokines, directly to the site of tumor growth. We envision that not only single cytokines but also cytokine combinations can be directed, at various times and intervals, to tumor tissues by transduced A-NK and T-LAK cells to induce strong and sustained antitumor immune responses. By not being dependent on injection of the genetic material directly into tumors, this technique can provide therapeutic benefit to multiple and remote tumors. In addition, achieving a selective, local production of cytokines should eliminate, or greatly reduce, the toxicity associated with systemic cytokine administration, since the cytokine effects will be concentrated right where they are needed, namely in the tumor tissue. This, in turn, should enhance the A-NK and T-LAK effectors' activity and survival, and, depending on the type of cytokines produced and host cells present in the tumor, should also boost various phases of the endogenous immune response.
